Hoth: Positive PHASE 1B CLINICAL TRIAL RESULTS IN MILD TO MODERATE ATOPIC DERMATITIS

 MEETS PRIMARY AND SECONDARY ENDPOINTS SAFETY AND EFFICACY

BIOLEXA led to significant improvement in disease severity as measured by SCORAD and EASI

Using the EASI scale, 100% of patients showed clinically relevant improvement >50% compared to Day 1 during the entire 28-day study treatment period

https://www.biospace.com/article/releases/hoth-therapeutics-reports-positive-biolexa-phase-1b-clinical-trial-results-in-mild-to-moderate-atopic-dermatitis/